Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Deng, Lan  [Clear All Filters]
2023
Feng C, Deng L, Yong Y-Y, Wu J-M, Qin D-L, Yu L, Zhou X-G, Wu A-G. The Application of Biomaterials in Spinal Cord Injury. Int J Mol Sci. 2023;24(1).
Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, Xu Y, Xu N, Luo Y, Deng L, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.
Zhang X, Pang Y, Wei C, Liang D, Yang S, Zhao C, Huang R, Deng L. Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes. Bone Marrow Transplant. 2023.
Yin Z, Su R, Ge L, Wang X, Yang J, Huang G, Li C, Liu Y, Zhang K, Deng L, et al. Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model. Int J Biol Sci. 2023;19(4):1211-1227.
Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, Chi P, Xu Y, Xu N, Deng L, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023.
2020
Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020.
2019
Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, Deng L, Liang X, Huang F, Fan Z, et al. Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. Biol Blood Marrow Transplant. 2019.
2014
Huang R, Tu S, Deng L, Kang Q, Song C, Li Y. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis. Hematology. 2014.